Why "research-grade" doesn't mean what you think

Open most peptide supplier websites and you'll see the same sentence: ≥98% pure, research-grade material. It's the industry's most-repeated line. It's also one of the most under-defined. There's no single regulator that polices what "research-grade" means in this category, and the gap between what suppliers print on a label and what actually arrives in the vial is the silent reproducibility problem in benchtop peptide research.

This piece is opinionated. We sell research peptides for a living, so take that for what it's worth. But the standards we describe below aren't ours, they're drawn from the published quality guidance for synthetic peptide therapeutics^[1] and from the analytical conventions every serious supplier already follows when they're being honest. Most don't talk about it because it costs money to do, and easier to assert than to prove.

What "98% purity" actually measures

Reversed-phase HPLC with UV detection at 214 nm, the wavelength where peptide bonds absorb most strongly^[2], separates the components of a peptide sample and quantifies them as a percentage of total area. A reading of 98% means 98% of what your detector sees is the target peptide. The remaining 2% is something else: typically truncation sequences (chains missing one or more residues), deletion sequences, oxidized variants, residual reagents, or trifluoroacetic acid (TFA) salts left over from the cleavage step in solid-phase peptide synthesis^[3].

None of those impurities are necessarily catastrophic. Some are. TFA salts in particular have been documented to interfere with cell-based assays and can shift dose-response curves in ways researchers attribute to the target compound when the target compound is innocent^[3]. Truncated sequences can compete for the same binding sites. The point isn't that 98% is too low, for most cell-based assays it's the accepted research-grade floor^[1], the point is that the 2% you don't see is where the noise in your data comes from.

Identity is a separate question

HPLC tells you purity. It does not tell you identity. A vial can be 99% pure and still be the wrong molecule. That's why a complete certificate of analysis pairs HPLC purity with mass spectrometry confirming the molecular weight and sequence^[1]. If a supplier ships a COA with one and not the other, treat it as half a document.

Stored intact at −20°C, lyophilized peptides typically maintain stability for 12-24+ months^[4]. The risk isn't the freezer, it's everything between the supplier's freezer and yours. A vial with a compromised seal exposed to ambient humidity for 24 hours can degrade more than a sealed vial that briefly hits 45°C in transit. Moisture ingress is the bigger threat, and it doesn't show up on the COA.

Where Lab X actually fits in

Lab X Peptides was built around one decision: documentation isn't a feature, it's the product. We work with independent testing laboratories on every batch we sell, and we ship lyophilized in vacuum-sealed vials with batch-specific COAs (HPLC + MS) available to qualifying institutions. We don't compete on price, there are cheaper suppliers, and we don't make claims about what the compounds do in the body, because that's not what research-use material is for.

What we sell is consistency. The same molecule, batch over batch, with the same documentation chain. For labs running longitudinal studies or planning to publish, that consistency is the only thing that lets you draw a clean line between your methodology and your results.

The honest test

If you've never done it, run a side-by-side. Order the same compound from your current supplier and from one alternative. Send both to the same independent lab for HPLC and MS. Compare the certificates against the actual results. The difference is the difference, and it's usually large.

Sourcing peptides isn't sexy work. It's procurement. But it's also the variable most labs underweight in their methodology, and the one that, when it goes wrong, looks exactly like a noisy assay until you spot it.